Seres Therapeutics (MCRB) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research report report published on Tuesday.

A number of other analysts also recently commented on MCRB. BidaskClub upgraded Seres Therapeutics from a strong sell rating to a sell rating in a research report on Friday, November 2nd. Chardan Capital reiterated a buy rating on shares of Seres Therapeutics in a research report on Sunday, October 28th. Bank of America downgraded Seres Therapeutics from a neutral rating to an underperform rating in a research report on Friday, August 3rd. Finally, Zacks Investment Research upgraded Seres Therapeutics from a sell rating to a hold rating in a research report on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Seres Therapeutics has an average rating of Hold and an average target price of $13.81.

MCRB opened at $8.40 on Tuesday. The company has a current ratio of 2.76, a quick ratio of 2.76 and a debt-to-equity ratio of 0.85. The firm has a market cap of $330.04 million, a price-to-earnings ratio of -3.80 and a beta of 0.61. Seres Therapeutics has a one year low of $5.64 and a one year high of $11.35.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.03. The company had revenue of $9.06 million for the quarter, compared to the consensus estimate of $23.43 million. Seres Therapeutics had a negative return on equity of 256.24% and a negative net margin of 264.31%. On average, equities analysts anticipate that Seres Therapeutics will post -2.41 earnings per share for the current year.

In other news, insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $5.94, for a total value of $84,817.26. Following the sale, the insider now directly owns 103,811 shares in the company, valued at $616,637.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Roger Pomerantz sold 12,518 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $9.10, for a total value of $113,913.80. Following the completion of the sale, the insider now owns 218,799 shares in the company, valued at $1,991,070.90. The disclosure for this sale can be found here. Insiders sold 69,634 shares of company stock worth $526,006 over the last 90 days. Company insiders own 37.10% of the company’s stock.

Several large investors have recently modified their holdings of MCRB. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Seres Therapeutics in the second quarter valued at $117,000. Bank of America Corp DE lifted its position in shares of Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 23,222 shares in the last quarter. Chicago Equity Partners LLC purchased a new stake in shares of Seres Therapeutics in the second quarter valued at $415,000. Schwab Charles Investment Management Inc. lifted its position in shares of Seres Therapeutics by 18.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after acquiring an additional 18,562 shares in the last quarter. Finally, Schroder Investment Management Group lifted its position in shares of Seres Therapeutics by 104.9% in the second quarter. Schroder Investment Management Group now owns 135,166 shares of the biotechnology company’s stock valued at $1,244,000 after acquiring an additional 69,205 shares in the last quarter. Institutional investors and hedge funds own 77.92% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Further Reading: Discover Your Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply